We will review the use of traditional complement proteins, C3 and C4, and compare them to complement activation (split) products in plasma and on cell surfaces in relation to their application to SLE diagnosis and monitoring of disease activity. This evidence concerns the gene C3 and systemic lupus erythematosus.